Mediamedic/LinkedIn
Sep 29, 2025, 16:19
Xue Feng Presented Her Work on AAV Vector–Based Gene Therapy
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Apr 13, 2026, 09:12We Are Pleased to Welcome Rajneesh Jain as the New Chief Executive Officer – Hemophilia Federation (India)
-
Apr 13, 2026, 08:52Deborah Holzapfel: The Reality for Women with Hemophilia B
-
Apr 13, 2026, 08:35Sara Altayeb: ESC 2026 Clinical Pearls for Bleeding on Anticoagulation
-
Apr 13, 2026, 07:58The Case for Greater Investment in VTE Research – JTH
-
Apr 13, 2026, 07:44Mattia Galli: A Clinicial Guide to Navigating Bleeding on Anticoagulant Therapy
-
Apr 13, 2026, 07:31Explore the Power of Guidelines in Hemophilia Care – EAHAD
-
Apr 13, 2026, 06:57Heghine Khachatryan: Why PNH Is More Than a Hemolytic Disease
-
Apr 13, 2026, 05:43Wolfgang Miesbach: A Historic Experiment That Changed Our Understanding of ITP
-
Apr 13, 2026, 04:49Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard